Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/intimm/dxab011 http://scihub22266oqcxt.onion/10.1093/intimm/dxab011 33715009!7989346!33715009     free     free     free       Int+Immunol 2021 ; 33 (10): 515-519 Nephropedia Template TP {{tp|p=33715009|t=2021. IL-6: from arthritis to CAR-T-cell therapy and COVID-19 |pdf=|usr=}}{{33715009}} gab.com Text IL-6: from arthritis to CAR-T-cell therapy and COVID-19 JO: Int Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33715009 #FOAvip Blockade of IL-6 function by an anti-IL-6 receptor (IL-6R) antibody (tocilizumab, trade name Actemra) has been shown to be effective for the treatment of chronic autoimmune inflammatory diseases including rheumatoid arthritis. Interestingly, treatment with tocilizumab has also been found to alleviate the cytokine storm induced by chimeric antigen receptor (CAR)-T-cell therapy. Patients with serious cases of coronavirus disease 2019 (COVID-19) exhibit cytokine release syndrome (CRS), which suggested that tocilizumab might be an effective therapeutic for serious cases of COVID-19. In the first part of this short review, the therapeutic effect of tocilizumab for the disease induced by IL-6 overproduction is described. CRS induced by CAR-T-cell therapy and COVID-19 is then discussed. Twit Text FOAVip IL-6: from arthritis to CAR-T-cell therapy and COVID-19 ????Int Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33715009 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33715009 #FOAvip English Wikipedia <ref>{{Cite pmid|33715009}}</ref> IL-6: from arthritis to CAR-T-cell therapy and COVID-19 #MMPMID33715009 Kishimoto T Int Immunol 2021[Sep]; 33 (10): 515-519 PMID33715009show ga Blockade of IL-6 function by an anti-IL-6 receptor (IL-6R) antibody (tocilizumab, trade name Actemra) has been shown to be effective for the treatment of chronic autoimmune inflammatory diseases including rheumatoid arthritis. Interestingly, treatment with tocilizumab has also been found to alleviate the cytokine storm induced by chimeric antigen receptor (CAR)-T-cell therapy. Patients with serious cases of coronavirus disease 2019 (COVID-19) exhibit cytokine release syndrome (CRS), which suggested that tocilizumab might be an effective therapeutic for serious cases of COVID-19. In the first part of this short review, the therapeutic effect of tocilizumab for the disease induced by IL-6 overproduction is described. CRS induced by CAR-T-cell therapy and COVID-19 is then discussed. |Arthritis/*immunology[MESH] |COVID-19/*immunology[MESH] |Cell- and Tissue-Based Therapy/methods[MESH] |Cytokine Release Syndrome/immunology[MESH] |Humans[MESH] |Interleukin-6/*immunology[MESH] |Receptors, Chimeric Antigen/*immunology[MESH]IL-6: from arthritis to CAR-T-cell therapy and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing